BioCentury
ARTICLE | Clinical News

Galactoarabino-rhamnogalacturonate: Completed Phase II enrollment

May 16, 2016 7:00 AM UTC

Galectin completed enrollment of 30 patients in the double-blind, placebo-controlled, U.S. Phase II NASH- FX trial evaluating 8 mg/kg GR-MD-02 every 2 weeks for 16 weeks. ...